Table 2.
Baseline characteristics of 198 patients who underwent endoscopic ultrasound-guided gastroenterostomy and enteral stenting.
| Variables | Overall n = 198 |
EUS-GE n = 66 |
ES n = 132 |
p Value ° |
|---|---|---|---|---|
| Age (years), mean ± SD | 67.2 ± 11.4 | 69.6 ± 11.4 | 66 ± 11.9 | 0.045 |
| Sex Male Female |
96 (48.5%) 102 (51.5%) |
38 (57.6%) 28 (42.4%) |
68 (51.5%) 64 (48.5%) |
0.420 |
| PS-ECOG 0–1 2 3–4 |
91 (46.0%) 64 (32.3%) 43 (21.7%) |
41 (62.1%) 16 (24.2%) 9 (13.7%) |
50 (37.9%) 48 (36.4%) 34 (25.7%) |
0.005 |
| Pre-procedural GOOSS * 0 1 Mean value ± SD |
132 (66.7%) 66 (27.7%) 0.38 ± 0.59 |
31 (47.0%) 35 (50.0%) 0.56 ± 0.55 |
101 (76.5%) 31 (16.7%) 0.25 ± 0.5 |
<0.0001 |
| Type of malignancy Pancreatic Other # |
139 (70.2%) 59 (29.8%) |
38 (57.6%) 28 (42.4%) |
101 (76.5%) 31 (23.4%) |
0.01 |
| Stage of disease Resectable/locally advanced Metastatic |
100 (50.5%) 98 (49.5%) |
32 (48.5%) 34 (51.5%) |
68 (51.5%) 64 (48.5%) |
0.373 |
| Ascites Yes No |
34 (17.2%) 164 (82.8%) |
2 (3.0%) 64 (97.0%) |
32 (24.2%) 100 (75.8%) |
<0.001 |
| Biliary obstruction Yes No |
128 (64.6%) 70 (35.4%) |
32 (48.5%) 34 (51.5%) |
96 (72.7%) 36 (27.3%) |
<0.001 |
| Stenosis location ** Type I Type II Type III |
70 (35.4%) 82 (41.4%) 46 (23.2%) |
20 (30.3%) 26 (39.4%) 20 (30.3%) |
50 (37.9%) 56 (42.4%) 26 (19.7%) |
0.229 |
| Follow-up duration, median (IQR), days | 90.5 (37–247) | 91.5 (42–189) | 92 (34–252) | 0.894 |
EUS-GE: endoscopic ultrasound-guided gastroenterostomy; ES: enteral stenting; SD: standard deviation; PS-ECOG: Eastern Cooperative Oncology Group performance status; GOOSS: gastric outlet obstruction score system. ° ES vs. EUS-GE. * According to Adler and Baron [23]; # Other includes duodenal (18, 9%), biliary (14, 7.1%), gastric (13, 6.6%), papillary (7, 3.5%), metastases (5, 2.6%), retroperitoneal tumors (2, 1.0%). ** According to the Mutignani classification [26].